Table 1.
Demographics, clinical characteristics, and nodule features
| Demographics and clinical characteristics | Median (IQR) or frequency (%) |
|---|---|
| n = 112 | |
| Age, years | 71 (64–76) |
| Sex | |
| Women | 60 (54%) |
| Men | 52 (46%) |
| Smoking history | 66 (59%) |
| Pack years | 25 (15–50) |
| Comorbidities | |
| Pulmonary Disease | 66 (59%) |
| Radiographic emphysema | 38 (34%) |
| COPD | 33 (29%) |
| Interstitial lung disease | 22 (20%) |
| Asthma | 11 (9.8%) |
| Chronic respiratory failure on home oxygen | 4 (3.6%) |
| Lung transplant | 3 (2.7%) |
| Sarcoidosis | 2 (1.8%) |
| Non-Pulmonary Disease | 105 (94%) |
| Hypertension | 51 (46%) |
| Hyperlipidemia | 36 (32%) |
| Prior Malignancy | 37 (33%) |
| Lung | 11 (9.8%) |
| Breast | 8 (7.1%) |
| Prostate | 6 (5.4%) |
| Hematologic | 6 (5.4%) |
| Uterine | 4 (3.6%) |
| Renal Cell | 3 (2.7%) |
| Melanoma | 2 (5.7%) |
| Bladder | 2 (1.8%) |
| Colon | 2 (1.8%) |
| Head and Neck | 2 (1.8%) |
| Pancreatic | 1 (0.9%) |
| Hepatocellular | 1 (0.9%) |
| With more than 1 malignancy | 9 (8%) |
| Cardiac disease/stroke | 23 (20.5%) |
| GERD | 20 (17.9%) |
| Diabetes mellitus II | 19 (17%) |
| Medications | |
| Antiplatelet agent* | 20 (17.8%) |
| Therapeutic anticoagulation** | 12 (10.7%) |
| Laboratory Values | |
| Platelet count × 109 per l | 249 (192.5–301) |
| International normalized ratio | 1 (1–1.1) |
| Blood urea nitrogen, mg/dL | 16 (13–22) |
| Creatinine, mg/dL | 0.89 (0.74–1.1) |
| Nodule Features | n = 120 |
|---|---|
| Location | |
| Right upper lobe | 35 (29.2%) |
| Right middle lobe | 10 (8.3%) |
| Right lower lobe | 30 (25%) |
| Left upper lobe | 28 (23.3%) |
| Lingula | 3 (2.5%) |
| Left lower lobe | 14 (11.7%) |
| Size | |
| Short axis, millimeters | 15.5 (8–25.3) |
| Long axis, millimeters | 22 (13–34.3) |
| Nodules 10 mm or under (long axis) | 19 (15.8%) |
| Nodules 11–20 mm | 39 (32.5%) |
| Nodules 21–30 mm | 27 (22.5%) |
| Nodules > 30 mm | 35 (29.2%) |
| Characteristics | |
| Solid | 87 (72.5%) |
| Part-solid | 25 (20.8%) |
| Ground glass | 8 (6.7%) |
| Bronchus sign present | 58 (48.3%) |
| Pleural distance, millimeters | 6 (0–15) |
| Procedure Details | |
| REBUS used | 120 (100%) |
| Concentric | 67 (55.8%) |
| Eccentric | 37 (30.8%) |
| No signal | 16 (13.3%) |
| Complications | n = 112 |
|---|---|
| Pneumothorax | 6 (5.4%) |
| Chest tube placement | 3 (2.7%) |
| Minor bleeding | 3 (2.7%) |
*Aspirin 81 mg was continued; if on clopidogrel, this was held 5 days prior to the procedure
**Any anticoagulant was held in the recommended period of time prior to the procedure
IQR interquartile range, COPD chronic obstructive pulmonary disease, GERD gastrointestinal reflux disease, mg milligrams, dL deciliter, REBUS radial endobronchial ultrasound